Genespire SRL

Genespire SRL develops innovative gene therapies targeting genetic diseases in children, focusing on immune-shielded lentiviral vectors for effective gene delivery. Founded in 2020, Genespire SRL operates from Milan, Italy, specializing in gene therapy innovations. The company has successfully completed 2 deals, the most recent being a EUR 46. 6 mn Series B funding round co-led by Sofinnova Partners, XGEN Venture, and CDP Venture Capital on September 25, 2024.

Julia Berretta serves as CEO. Genespire focuses on the development of innovative gene therapies tailored to address genetic diseases in children. Their primary offering includes immune-shielded lentiviral vectors, which deliver therapeutic genes into patient cells while minimizing immune responses that typically hinder treatment effectiveness. These products aim to improve health outcomes for children with genetic disorders and are advancing through clinical development phases.

The company primarily serves the European market, particularly in regions where access to advanced therapeutic options is limited. Genespire generates revenue through strategic partnerships with healthcare institutions and pharmaceutical companies engaged in gene therapy innovations. The company’s financial framework is supported by collaboration agreements and research partnerships, which may include milestone payments associated with clinical trials and regulatory approvals, as well as potential licensing agreements for their proprietary technologies. The firm’s flagship offering positions it for transactions that may involve shared revenue models based on future sales of successful treatments.

In 2023, the company reported an EBITDA of EUR -7,921,707. 30. In September 2024, Genespire SRL raised EUR 46. 6 mn in Series B funding to support the development of GENE2022.

The company plans to expand its product offerings and geographic reach, particularly targeting markets within Europe where genetic diseases are prevalent. Recent funding will be utilized for advancing their product pipeline and enhancing their capabilities in clinical trials.